$86.54
2.11% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US46116X1019
Symbol
ITCI
Sector
Industry

Intra-Cellular Therapies, Inc. Target price 2024 - Analyst rating & recommendation

Intra-Cellular Therapies, Inc. Classifications & Recommendation:

Buy
88%
Hold
13%

Intra-Cellular Therapies, Inc. Price Target

Target Price $100.80
Price $86.54
Potential
Number of Estimates 15
15 Analysts have issued a price target Intra-Cellular Therapies, Inc. 2025 . The average Intra-Cellular Therapies, Inc. target price is $100.80. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 14 Analysts recommend Intra-Cellular Therapies, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Intra-Cellular Therapies, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Intra-Cellular Therapies, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 464.37 672.68
85.52% 44.86%
EBITDA Margin -34.21% -16.12%
67.44% 52.88%
Net Margin -33.21% -9.38%
71.07% 71.75%

15 Analysts have issued a sales forecast Intra-Cellular Therapies, Inc. 2024 . The average Intra-Cellular Therapies, Inc. sales estimate is

$673m
Unlock
. This is
19.16% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$681m 20.63%
Unlock
, the lowest is
$656m 16.20%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $464m 85.52%
2024
$673m 44.86%
Unlock
2025
$934m 38.84%
Unlock
2026
$1.4b 50.25%
Unlock
2027
$2.0b 42.50%
Unlock
2028
$2.6b 30.93%
Unlock

7 Analysts have issued an Intra-Cellular Therapies, Inc. EBITDA forecast 2024. The average Intra-Cellular Therapies, Inc. EBITDA estimate is

$-108m
Unlock
. This is
3.11% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-84.0m 24.97%
Unlock
, the lowest is
$-134m 19.42%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-159m 39.59%
2024
$-108m 31.72%
Unlock
2025
$-6.4m 94.09%
Unlock
2026
$323m 5,134.01%
Unlock
2027
$842m 160.60%
Unlock
2028
$1.8b 115.53%
Unlock

EBITDA Margin

2023 -34.21% 67.44%
2024
-16.12% 52.88%
Unlock
2025
-0.69% 95.72%
Unlock
2026
23.01% 3,434.78%
Unlock
2027
42.09% 82.92%
Unlock
2028
69.28% 64.60%
Unlock

12 Intra-Cellular Therapies, Inc. Analysts have issued a net profit forecast 2024. The average Intra-Cellular Therapies, Inc. net profit estimate is

$-63.1m
Unlock
. This is
30.52% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-37.0m 59.30%
Unlock
, the lowest is
$-77.1m 15.12%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-154m 46.32%
2024
$-63.1m 59.07%
Unlock
2025
$54.8m 186.80%
Unlock
2026
$389m 609.86%
Unlock
2027
$825m 112.06%
Unlock
2028
$1.2b 47.55%
Unlock

Net Margin

2023 -33.21% 71.07%
2024
-9.38% 71.75%
Unlock
2025
5.87% 162.58%
Unlock
2026
27.71% 372.06%
Unlock
2027
41.24% 48.83%
Unlock
2028
46.47% 12.68%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.46 -0.60
46.32% 58.90%
P/E negative
EV/Sales 12.14

12 Analysts have issued a Intra-Cellular Therapies, Inc. forecast for earnings per share. The average Intra-Cellular Therapies, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.60
Unlock
. This is
30.23% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.35 59.30%
Unlock
, the lowest is
$-0.73 15.12%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.46 46.32%
2024
$-0.60 58.90%
Unlock
2025
$0.52 186.67%
Unlock
2026
$3.68 607.69%
Unlock
2027
$7.81 112.23%
Unlock
2028
$11.52 47.50%
Unlock

P/E ratio

Current -100.29 300.68%
2024
-144.84 44.42%
Unlock
2025
166.84 215.19%
Unlock
2026
23.51 85.91%
Unlock
2027
11.08 52.87%
Unlock
2028
7.51 32.22%
Unlock

Based on analysts' sales estimates for 2024, the Intra-Cellular Therapies, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

12.14
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
13.64
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 14.47 27.04%
2024
12.14 16.08%
Unlock
2025
8.75 27.97%
Unlock
2026
5.82 33.44%
Unlock
2027
4.08 29.83%
Unlock
2028
3.12 23.63%
Unlock

P/S ratio

Current 16.25 27.44%
2024
13.64 16.08%
Unlock
2025
9.82 27.97%
Unlock
2026
6.54 33.44%
Unlock
2027
4.59 29.83%
Unlock
2028
3.50 23.63%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today